ImmunGene partners with Cephalon Australia for interferon payload technology
THOUSAND OAKS, Calif.—ImmunGene Inc., a privately held drug development company focused on targeted antibody therapeutics, has entered into a collaboration in which Cephalon Australia—a wholly owned subsidiary of Cephalon Inc.—will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers. Under terms of the collaboration, Cephalon will pay undisclosed fees including an upfront payment to ImmunGene for a four-year option to leverage ImmunGene's novel drug development technology in preclinical research. Cephalon has the option to pay ImmunGene license fees for exclusivity on candidates that it decides to move into clinical trials. Cephalon is responsible for research, clinical development, manufacturing and commercialization of products that result from the ImmunGene collaboration. ImmunGene is eligible to receive considerable payments for research, clinical and regulatory milestones for each drug candidate in the collaboration that is commercialized, in addition to royalties on worldwide net sales of any resulting products.